PRGO - Rasio utang marang kapitalisasi buku Perrigo Company PLC

Logo grafis Perrigo Company PLC (PRGO)

This chart illustrates that the market value of Perrigo Company plc (PRGO) on the GURU.Markets platform is 1.30. Management is currently restructuring its strategy to focus on health products and reduce debt. Distribution relies on accessible warehouse logistics, ensuring uninterrupted supplies to pharmacies. Meanwhile, the development of private labels allows the company to lower production costs and maintain stable business profitability.

PRGO (Perrigo Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 27.10.2026
Barang utama Perrigo Company

This indicator measures the extent to which all liabilities are covered by net assets, allowing for an assessment of financial stability and debt load risk during business recovery. An analysis of the debt-to-equity ratio for Perrigo Company plc (PRGO) confirms its status as a defensive asset, as demand for affordable Private Label products during a recession stabilizes the capital base, minimizing default risks for the investor.

Pesaing Perrigo Company plc

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|ALVO (Alvotech) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku liquidia.com (LQDA)|Galapagos (GLPG) - Utang marang nilai buku|Rasio utang marang aset resik ANIP (ANI Pharmaceuticals Inc)|MNKD: Rasio utang marang kapitalisasi buku|AMPH - Utang-utang marang nilai buku|Utang marang nilai buku Pacira BioSciences PCRX|SPRY - Utang marang modal buku|Utang-utang marang kapitalisasi buku Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku SCPH (scPharmaceuticals, Inc.)|Utang-utang marang nilai buku TECX|Tonix Pharmaceuticals (TNXP) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. (EPRX) - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku BioHarvest Sciences, Inc. BHST|EXOZ (Invizyne Technologies, Inc.) - Utang-utang marang kapitalisasi buku|ORMP: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku enterabio.com ENTX|HYFT (ipatherapeutics.com) - Rasio utang marang aset resik|ABVC - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik Cumberland Pharmaceuticals Inc|QNTM (Quantum BioPharma Limited) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik FibroGen Corporation (FGEN)|TELO (Telomir Pharmaceuticals) - Utang-utang marang kapitalisasi buku|Rani Therapeutics Holdings - Utang marang aset resik|SNYR (Synergy CHC Corporation) - Rasio utang marang kapitalisasi buku|Rallybio Corporation (RLYB) - Utang-utang marang nilai buku|Utang marang nilai buku lexariabioscience.com LEXX|Pulmatrix Corporation (PULM) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku PTHL|Utang marang nilai buku APM|Lyra Therapeutics - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku IBO (Impact BioMedical, Inc.)|TNF Pharmaceuticals, Inc. - Rasio utang marang kapitalisasi buku|cbdMD Inc. - Utang marang nilai buku|Rasio utang marang kapitalisasi buku PainReform Ltd.|CYTO - Rasio utang-utang marang kapitalisasi buku|LIPO: Utang-utang marang kapitalisasi buku|OPTN (OptiNose Inc) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Pieris (PIRS)|Rasio utang marang nilai buku Procaps Group Corp (PROC)|Petros Pharmaceuticals - Utang marang nilai buku|Utang-utang marang nilai buku qlsyy.net QLI|Utang marang nilai buku ACELYRIN|TFF Pharmaceuticals Inc. - Rasio utang marang aset resik